Cannabix Technologies Inc., a company listed on the CSE under the symbol BLO, has officially initiated the commercial phased rollout of its Marijuana Breath Test (MBT) system. Based in Vancouver, British Columbia, the company announced on March 16, 2026, that it is delivering MBT units to select commercial customers across various industries, with plans to scale up production in the near future.
Addressing a Critical Need in Cannabis Detection
The Marijuana Breath Test system is designed to fill a significant gap in current testing methodologies by providing a complete, non-invasive solution for detecting recent cannabis use. Specifically, it identifies delta-9 THC, the primary psychoactive compound in cannabis, in breath samples within approximately four hours of consumption at levels above 5 pg/L. This capability is crucial as it allows for the accurate detection of recent use, unlike traditional methods that often only indicate past consumption.
With the expansion of legalized recreational and medical marijuana use across the United States and globally, there is a growing demand for reliable tools to ensure fairness and informed decision-making in safety-sensitive environments. The MBT system aims to meet this need by offering a practical alternative for employers, law enforcement agencies, and other industries where monitoring recent cannabis use is essential for maintaining safety and compliance.
Key Developments and Validations
In early March 2026, an independent peer-reviewed publication in the Journal of Analytical Toxicology became publicly available, confirming the MBT system's ability to detect delta-9 THC. This validation underscores the scientific credibility of the technology and supports its commercial deployment.
Over recent months, Cannabix and its partners have undertaken several initiatives to facilitate the rollout of the MBT system. These include:
- Key enhancements to the Breath Collection Unit (BCU) and Breath Cartridges, along with an initial validation package prepared by Omega Laboratories.
- Integration of Cannabix Breath Cartridges into Omega's operational workflows, including chain-of-custody processes and electronic reporting through its Laboratory Information Management System (LIMS).
- Establishment of manufacturing procedures, partnerships, standard operating procedures, and quality assurance/quality control processes for MBT hardware.
- Successful completion of FCC electronic emissions testing for the BCU.
- Pre-launch marketing initiatives conducted with Omega in Ohio and AlcoPro in Knoxville, Tennessee.
- Preparation of end-user training materials, logistics planning, and customer support resources.
Business Model and Future Prospects
The MBT system will operate on a recurring revenue model, where the handheld BCU serves as the necessary hardware for all deployments, while disposable Breath Cartridges generate ongoing revenue with each test performed. This approach is expected to provide a steady income stream as adoption increases.
As Cannabix moves forward with its commercial rollout, the company is poised to address the evolving needs of industries grappling with the challenges of cannabis legalization. By offering a non-invasive and accurate method for detecting recent THC use, the MBT system represents a significant advancement in technology that could enhance safety protocols and regulatory compliance worldwide.
